✦ LIBER ✦

Clinical Characteristics of EGFR-TKI–Induced Interstitial Pneumonitis in Korean Non–Small-Cell Lung Cancer Patients

✍ Scribed by In-Jae Oh; Song Choi; Yong-Soo Kwon; Kyu-Sik Kim; Yu-Il Kim; Sung-Chul Lim; Young-Chul Kim; Yun-Hyeon Kim

Book ID: 115076742
Publisher: CIG Media Group, LP.
Year: 2009
Tongue: English
Weight: 42 KB
Volume: 10
Category: Article
ISSN: 1525-7304
DOI: 10.3816/clc.2009.n.066

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mechanisms of EGFR-TKI induced cell deat

Mechanisms of EGFR-TKI induced cell death and resistance in EGFR mutant non-small cell lung cancer

✍ J. Ko; Y. Kim; M. Park; Z. Cui; M. Ahn; K. Park 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 100 KB

Beyond EGFR TKI in EGFR-mutant Non-Small

Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome

✍ Remon, J.; Morán, T.; Reguart, N.; Majem, M.; Carcereny, E.; Lianes, P. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 525 KB

EGFR, ERBB2, and KRAS mutations in Korea

EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients

✍ Nack Cheon Bae; Myung Hwa Chae; Myung Hoon Lee; Kyung Mee Kim; Eung Bae Lee; Cha 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 515 KB

Gefitinib-induced pneumonitis in non-sma

Gefitinib-induced pneumonitis in non-small cell lung cancer: radiological and clinical findings in five patients

✍ Hee Sun Park; Hyun Ju Lee; Jung-Gi Im; Jin Mo Goo; Chang-Hyun Lee; Chang Min Par 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 410 KB

Reaction of plasma hepatocyte growth fac

Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs

✍ Hidenori Tanaka; Tatsuo Kimura; Shinzoh Kudoh; Shigeki Mitsuoka; Tetsuya Watanab 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 242 KB

## Abstract Hepatocyte growth factor induces resistance to epidermal growth factor receptor tyrosine kinase inhibitors. It has been hypothesized that epidermal growth factor receptor tyrosine kinase inhibitors administration may influence the levels of plasma hepatocyte growth factor. Patients with

EGFR-TKI Therapy Prolongs Survival In No

EGFR-TKI Therapy Prolongs Survival In Non-small Cell Lung Cancer Patients With Brain Metastases or Bone Metastases

✍ Hui, L.; Xiaomei, G.; Wei, J.; Chunxue, B.; Zhaochong, Z. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB